AstraZeneca to Spend $190M for New UK Facility
AstraZeneca announced plans to invest $190 million in a new facility at its global manufacturing site in Macclesfield, UK, to continue production of Zoladex, an injectable treatment for patients with prostate cancer. The investment secures 300 existing Zoladex jobs at the site and will create more than 200 temporary jobs during the construction and commissioning phase between now and early 2017. Read the full story